Company & Sponsor Intelligence

Capital Medical University

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting1

Completed1

Countries1

Therapeutic footprint

alzheimersstroke

Indexed studies

NCT07263776Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
stroke · ChinaPHASE3

NCT01672515Protective Effects of Remote Limb Ischemic Preconditioning on Acute Cerebral Infarction
stroke · PHASE1, PHASE2

NCT05269173Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease
alzheimers · ChinaPHASE2

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →